Biohaven Ltd. (BHVN)’s BHV-1400 Cuts Disease Antibody by 81% in IgA Nephropathy

Biohaven Ltd. (NYSE:BHVN) has announced major breakthroughs with its novel precision immunology therapies, BHV-1400 and BHV-1300, at its 2025 R&D Day in New Haven. BHV-1400, a first-in-class TRAP degrader, achieved up to 81% reduction in galactose-deficient IgA1 (Gd-IgA1), the key driver of IgA nephropathy (IgAN), after a single subcutaneous dose, with effects lasting for weeks.

 Biohaven Ltd. (BHVN)’s BHV-1400 Cuts Disease Antibody by 81% in IgA Nephropathy

A patient viewing their medical diagnosis on a digital healthcare ecosystem.

Unlike traditional immunosuppressive treatments, BHV-1400 precisely eliminates pathogenic Gd-IgA1 while sparing healthy antibodies (IgA, IgG, IgE, IgM), preserving overall immune function and offering a superior safety profile. This selectivity sets it apart from complement and BLyS/APRIL inhibitors, which can compromise broader immunity. Encouraged by these results, Biohaven Ltd. (NYSE:BHVN) will launch a pivotal IgAN trial in 2026 using the urine protein-creatinine ratio as an accelerated approval endpoint.

Simultaneously, BHV-1300, targeting IgG-mediated diseases like Graves’ Disease, demonstrated rapid, deep, and sustained total IgG reductions of up to 87% in Phase 1, with flexible dosing for acute and chronic management. Both therapies were well-tolerated, with no serious adverse events.

Biohaven Ltd. (NYSE:BHVN) plans pivotal trials for BHV-1300 in Graves’ Disease in the second half of 2025, reinforcing its leadership in precision immunology.

While we acknowledge the potential of BHVN to grow, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk.  If you are looking for an AI stock that is more promising than BHVN and that has 100x upside potential, check out our report about this cheapest AI stock.

READ NEXT: 10 Best Cancer Stocks to Invest in for Long-Term Gains and 10 Most Oversold Stocks to Buy According to Billionaires.

Disclosure: None.